DBM-819

• Description :

  DBM-819 is a reversible inhibitor of H⁺/K⁺-ATPase (H+/K+-ATPase), with an IC50 value of 5 μM. DBM-819 can reversibly block gastric acid secretion by inhibiting the proton pump in the gastric mucosa. It shows significant protective effects against duodenal ulcers induced by Cysteamine (HY-77591), gastric ulcers induced by Indomethacin (HY-14397), and gastric ulcers induced by Aspirin (HY-14654), with EC50 values of 6, 3.1, and 4 mg/kg respectively. DBM-819 can be used in ulcer prevention research[1][2].

• UNSPSC :

  12352005

• Target :

  Na+/K+ ATPase

• Related Pathways :

  Membrane Transporter/Ion Channel

• Field of Research :

  Metabolic Disease

• Smiles :

  OCCCNC1=C(CCN2C3=CC=C(C=C3C)OC)C2=C(C=CC=C4C)C4=N1

• Molecular Formula :

  C23H27N3O2

• Molecular Weight :

  377.48

• References & Citations :

  [1]Choi SJ, et al. In vitro metabolism of a new H (+) /K (+) ATPase inhibitor DBM-819 in liver microsomes using HPLC and electrospray mass spectrometry. Biomed Chromatogr. 2001 Dec;15 (8) :503-6.|[2]Kim EJ, et al. Dose-dependent pharmacokinetics of a new reversible proton pump inhibitor, DBM-819, after intravenous and oral administration to rats: hepatic first-pass effect. Biopharm Drug Dispos. 2001 Apr;22 (3) :119-28.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [331686-58-9]